MOTS-c Dosage: Why There Is No Established Human Dose, and What Prescribers Should Know

This article is educational and written for licensed prescribers. It is not medical advice, and it does not recommend a dose for any patient.

People searching for a MOTS-c dosage usually expect a number. The honest answer is that there is no established human dose of MOTS-c — not a labeled dose, not a dose validated in controlled human trials, and not one that FDA's recent review could evaluate. That is not a gap this article can fill by quoting a range from a forum or a vendor. What it can do is explain why the gap exists, what the research does and does not show, and what a prescriber should weigh when a patient asks.

For what MOTS-c is and how it works, start with our MOTS-c peptide overview. This page covers dosing only.

MOTS-c Dosage: The Short Answer

There is no evidence-based MOTS-c dose for humans. Specifically:

• No approved product. MOTS-c is not an FDA-approved drug, so there is no prescribing information and no labeled dose.
• No human effectiveness data. In the briefing for the July 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting, FDA concluded there is a lack of evidence to evaluate MOTS-c's effectiveness in humans for the nominated metabolic uses.
• No human safety data. FDA was "particularly concerned" about the absence of human data by any route — see MOTS-c and the FDA 503A decision.

Any MOTS-c dose used in practice is therefore a prescriber-determined judgment made without controlled human evidence behind it.

Why There Is No Established Human Dose

The Research Is Almost Entirely Preclinical

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, first described in 2015. Its best-known effects — improved insulin sensitivity, reduced hepatic lipid accumulation, better metabolic flexibility — come from rodent studies, mostly in diet-induced obesity and aging models. In those studies it was typically given by intraperitoneal or subcutaneous injection.

Rodent research establishes that a molecule does something in a rodent. It does not establish the dose, frequency, or duration that would do something useful and safe in a person.

Rodent Doses Do Not Convert Directly

It is tempting to take a milligram-per-kilogram figure from a mouse study and scale it to a human. That approach is unreliable. Metabolic rate, clearance, and body surface area differ substantially across species, and formal conversion methods exist precisely because naive weight-based scaling can be off by a wide margin. Even a correctly scaled estimate only gives a starting point for human dose-finding studies. It is not a substitute for them, and those studies have not been done for MOTS-c.

Documented Human Use Is Absent

FDA's briefing also reported that published literature showed no studies in which compounded MOTS-c was used in humans, and that outsourcing facilities did not report compounding it. The internet presents MOTS-c mainly as an injectable, alone and in combinations, but that marketing is not a clinical record.

What FDA's Review Means for Dosing

The regulatory position shapes the dosing question directly. As of the site's July 2026 sources:

A PCAC proposal is advisory, not a final determination, and status can change. Check the FDA peptide status tracker for the current position, and see the July 2026 FDA review explained for the broader context.

The Numbers You See Online

Protocols circulating online quote specific MOTS-c amounts, schedules, and cycle lengths. They tend to share three weaknesses:

1. No traceable human source. The figures are rarely tied to a human study, because the relevant human studies have not been published.
2. Product uncertainty. Much of the MOTS-c sold outside legitimate prescription channels is labeled "for research use," with no assurance of identity, purity, sterility, or content.
3. Survivorship in anecdotes. Self-reported results cannot separate the peptide's effect from diet, training, placebo, or co-administered compounds.

None of this proves MOTS-c is ineffective in people. It means the numbers do not carry the evidential weight their precision suggests, and they should not be treated as a dosing reference.

Safety Questions a Dose Can't Answer

Even if a dose were chosen, key safety questions would remain open:

• Immunogenicity. FDA flagged that injected MOTS-c may pose immunogenicity risk because of potential aggregate formation and impurities, and noted the information needed to assess that risk was not provided.
• Long-term exposure. There are no long-term human safety data at any dose.
• Metabolic interactions. MOTS-c is studied for effects on glucose handling. Its interaction with glucose-lowering therapies has not been characterized in humans.
• Stability and handling. FDA reported lyophilized MOTS-c free base as stable below −20°C when desiccated and protected from light. Handling outside those conditions adds another source of variability.

What a Prescriber Can Reasonably Do

When a patient asks about MOTS-c, a defensible approach looks like this:

1. Be explicit about the evidence. There is no established human dose and no human effectiveness data. Informed consent should say so plainly.
2. Ask about current use. Patients may already be using MOTS-c obtained elsewhere. Sourcing, product labeling, and any co-administered compounds are clinically relevant.
3. Establish a metabolic baseline if a patient is using it or intends to — glucose markers and a standard metabolic panel give a reference point.
4. Consider approaches with human evidence first. Exercise itself is the intervention MOTS-c is sometimes described as mimicking, and FDA noted that approved therapies exist for several of the nominated metabolic uses.
5. Confirm compounding status with the 503A partner rather than assuming availability.

For a comparison with another investigational "exercise mimetic," see SLU-PP-332 vs MOTS-c. For the wider longevity picture, see our guide to anti-aging peptides.

Newtropin does not prescribe, compound, or dispense. We connect licensed providers with a licensed 503A compounding partner; prescribers can start at For Providers.

Frequently Asked Questions

What is the standard MOTS-c dosage?

There isn't one. MOTS-c is not FDA-approved, has no labeled dose, and — per FDA's July 2026 review — has no human effectiveness or safety data to base a dose on. Any dose is a prescriber judgment made without controlled human evidence.

Can a MOTS-c dose be calculated from animal studies?

Not reliably. Direct weight-based scaling from rodents is inaccurate, and even formal species conversions only give a starting point for human dose-finding studies, which have not been done for MOTS-c.

Is MOTS-c legal to prescribe through a compounding pharmacy?

FDA proposed in July 2026 that MOTS-c not be added to the 503A Bulks List. The proposal is advisory rather than final, so check the FDA peptide status tracker and confirm with the compounding partner before assuming availability.

How is MOTS-c usually administered?

Preclinical studies used intraperitoneal or subcutaneous injection, and online marketing presents it mainly as an injectable. FDA flagged potential immunogenicity with injection as an unaddressed safety concern.

Are the MOTS-c doses posted online safe?

Their safety is unknown. They are generally not traceable to human studies, and products sold "for research use" carry no assurance of identity, purity, or sterility.